Literature DB >> 19428080

Alpha-blocker use is associated with decreased risk of sexual dysfunction.

Rajeev Kumar1, Ajay Nehra, Debra J Jacobson, Michaela E McGree, Naomi M Gades, Michael M Lieber, Steven J Jacobsen, Jennifer L St Sauver.   

Abstract

OBJECTIVES: To examine the association between alpha-blocker use and sexual dysfunction among men participating in a population-based cohort of men residing in Olmsted County, MN. Lower urinary tract symptoms (LUTS) in men have previously been associated with sexual dysfunction. The use of alpha-adrenergic receptor blocking agents results in an improvement in LUTS for many men. If sexual dysfunction and LUTS share a common etiology, alpha-blocker use might also be associated with a decreased risk of sexual dysfunction.
METHODS: White men, aged 40-79 years, were randomly selected in 1990 and assessed for alpha-blocker use and LUTS severity. Sexual function was assessed using the Brief Male Sexual Function Inventory. Men who used alpha-blockers before any sexual dysfunction were considered "exposed." Hazard ratios and 95% confidence intervals were estimated separately for each sexual function domain using Cox proportional hazard models.
RESULTS: Of the 1724 men with a regular sexual partner included in the present study (mean age 57.74 years), 263 (15.3%) reported alpha-blocker use. alpha-Blocker use was associated with a decreased risk of sexual dysfunction across all domains for men > or =50 years old (age-adjusted hazard ratio 0.53-0.69). A decreased risk of erectile dysfunction and low libido remained significant only among those using alpha-blockers who also experienced an improvement in LUTS (P = .01).
CONCLUSIONS: The use of alpha-blockers for LUTS was associated with a decreased risk of sexual dysfunction. Improvement in sexual function correlated with the improvement in LUTS more strongly among those using alpha-blockers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428080      PMCID: PMC2862577          DOI: 10.1016/j.urology.2008.12.080

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  15 in total

1.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

2.  Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'.

Authors:  M Braun; G Wassmer; T Klotz; B Reifenrath; M Mathers; U Engelmann
Journal:  Int J Impot Res       Date:  2000-12       Impact factor: 2.896

3.  Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial.

Authors:  Sara T Brookes; Jenny L Donovan; Tim J Peters; Paul Abrams; David E Neal
Journal:  BMJ       Date:  2002-05-04

Review 4.  Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction.

Authors:  I Goldstein
Journal:  Int J Impot Res       Date:  2000-03       Impact factor: 2.896

5.  Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction.

Authors:  Roger S Kirby; Michael P O'Leary; Culley Carson
Journal:  BJU Int       Date:  2005-01       Impact factor: 5.588

6.  Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.

Authors:  K Höfner; H Claes; T M De Reijke; B Folkestad; M J Speakman
Journal:  Eur Urol       Date:  1999-10       Impact factor: 20.096

7.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

Authors:  J E Oesterling; S J Jacobsen; C G Chute; H A Guess; C J Girman; L A Panser; M M Lieber
Journal:  JAMA       Date:  1993-08-18       Impact factor: 56.272

8.  A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men.

Authors:  S J Jacobsen; H A Guess; L Panser; C J Girman; C G Chute; J E Oesterling; M M Lieber
Journal:  Arch Fam Med       Date:  1993-07

9.  Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

Authors:  Raymond Rosen; Jens Altwein; Peter Boyle; Roger S Kirby; B Lukacs; Eric Meuleman; Michael P O'Leary; Paolo Puppo; Chris Robertson; Francois Giuliano
Journal:  Eur Urol       Date:  2003-12       Impact factor: 20.096

10.  Distribution of the Brief Male Sexual Inventory in community men.

Authors:  M P O'Leary; T Rhodes; C J Girman; D J Jacobson; R O Roberts; M M Lieber; S J Jacobsen
Journal:  Int J Impot Res       Date:  2003-06       Impact factor: 2.896

View more
  4 in total

Review 1.  The Complex Relationship Between Lower Urinary Tract Symptoms and Sexual Health.

Authors:  Hanson Zhao; Howard H Kim
Journal:  Curr Urol Rep       Date:  2019-08-29       Impact factor: 3.092

2.  Molecular biology research in neuropsychiatry: India's contribution.

Authors:  T S Sathyanarayana Rao; B N Ramesh; P Vasudevaraju; K S J Rao
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

3.  Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin.

Authors:  Kyungtae Ko; Dae Yul Yang; Won Ki Lee; Sae Woong Kim; Du Geon Moon; Ki Hak Moon; Nam Cheol Park; Jong Kwan Park; Hwan Cheol Son; Sung Won Lee; Jae Seog Hyun; Kwangsung Park
Journal:  Korean J Urol       Date:  2014-09-05

4.  Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study.

Authors:  Smita Pattanaik; Harbhupinder Singh Sandhu; Ravimohan Suryanarayan Mavuduru; Shrawan Kumar Singh; Arup Kumar Mandal
Journal:  Indian J Urol       Date:  2019 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.